Genome-wide association studies in pharmacogenomics of antidepressants

Papers of special note have been highlighted as: • of interest; •• of considerable interest.

References

• 1 Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3(11), e442 (2006).
  MedlineGoogle Scholar
• 2 Lin E, Chen PS. Pharmacogenomics with antidepressants in the STAR*D study. Pharmacogenomics 9(7), 935–946 (2008).• Review on pharmacogenomics of antidepressants based on the literature up to 2008.
  CASGoogle Scholar
• 3 Murphy E, McMahon FJ. Pharmacogenetics of antidepressants, mood stabilizers, and antipsychotics in diverse human populations. Discov. Med. 16(87), 113–122 (2013).
  MedlineGoogle Scholar
• 4 Fabbri C, Porcelli S, Serretti A. From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment. Can. J. Psychiatry 59(2), 62–75 (2014).
  MedlineGoogle Scholar
• 5 Johnson AD, O'Donnell CJ. An open access database of genome-wide association results. BMC Med. Genet. 10, 6 (2009).
  MedlineGoogle Scholar
• 6 Christensen K, Murray JC. What genome-wide association studies can do for medicine. N. Engl. J. Med. 356(11), 1094–1097 (2007).• Review on genome-wide association studies.
  Medline CASGoogle Scholar
• 7 Need AC, Goldstein DB. Whole genome association studies in complex diseases: where do we stand? Dialogues Clin. Neurosci. 12(1), 37–46 (2010).
  MedlineGoogle Scholar
• 8 Pearson TA, Manolio TA. How to interpret a genome-wide association study. JAMA 299(11), 1335–1344 (2008).
  Medline CASGoogle Scholar
• 9 Goldstein DB. Common genetic variation and human traits. N. Engl. J. Med. 360(17), 1696–1698 (2009).
  Medline CASGoogle Scholar
• 10 Rosenberg NA, Huang L, Jewett EM, Szpiech ZA, Jankovic I, Boehnke M. Genome-wide association studies in diverse populations. Nat. Rev. Genet. 11(5), 356–366 (2010).
  Medline CASGoogle Scholar
• 11 Elbers CC, van Eijk KR, Franke L et al. Using genome-wide pathway analysis to unravel the etiology of complex diseases. Genet. Epidemiol. 33(5), 419–431 (2009).
  MedlineGoogle Scholar
• 12 Cantor RM, Lange K, Sinsheimer JS. Prioritizing GWAS results: a review of statistical methods and recommendations for their application. Am. J. Hum. Genet. 86(1), 6–22 (2010).
  Medline CASGoogle Scholar
• 13 Ising M, Lucae S, Binder EB et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch. Gen. Psychiatry 66(9), 966–975 (2009).•• First genome-wide association study in pharmacogenomics of antidepressants.
  Medline CASGoogle Scholar
• 14 Garriock HA, Kraft JB, Shyn SI et al. A genomewide association study of citalopram response in major depressive disorder. Biol. Psychiatry 67(2), 133–138 (2010).
  Medline CASGoogle Scholar
• 15 Uher R, Perroud N, Ng MY et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am. J. Psychiatry 167(5), 555–564 (2010).
  MedlineGoogle Scholar
• 16 Tansey KE, Guipponi M, Perroud N et al. Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. PLoS Med. 9(10), e1001326 (2012).
  MedlineGoogle Scholar
• 17 Hunter AM, Leuchter AF, Power RA et al. A genome-wide association study of a sustained pattern of antidepressant response. J. Psychiatr. Res. 47(9), 1157–1165 (2013).
  MedlineGoogle Scholar
• 18 Clark SL, Adkins DE, Aberg K et al. Pharmacogenomic study of side effects for antidepressant treatment options in STAR*D. Psychol. Med. 42(6), 1151–1162 (2012).
  Medline CASGoogle Scholar
• 19 Adkins DE, Clark SL, Åberg K et al. Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D. Transl. Psychiatry 2, e129 (2012).
  Medline CASGoogle Scholar
• 20 Laje G, Allen AS, Akula N, Manji H, John Rush A, McMahon FJ. Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. Pharmacogenet. Genomics 19(9), 666–674 (2009).
  Medline CASGoogle Scholar
• 21 Perroud N, Uher R, Ng MY et al. Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project. Pharmacogenomics J. 12(1), 68–77 (2012).
  Medline CASGoogle Scholar
• 22 Chen RY, Cao JJ, Chen J et al. Single nucleotide polymorphisms in the CDH17 gene of colorectal carcinoma. World J. Gastroenterol. 18(48), 7251–7261 (2012).
  MedlineGoogle Scholar
• 23 Ikeda M, Aleksic B, Kinoshita Y et al. Genome-wide association study of schizophrenia in a Japanese population. Biol. Psychiatry 69(5), 472–478 (2011).
  MedlineGoogle Scholar
• 24 Rush AJ, Fava M, Wisniewski SR et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin. Trials 25(1), 119–142 (2004).
  MedlineGoogle Scholar
• 25 Trivedi MH, Rush AJ, Wisniewski SR et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice, Am. J. Psychiatry 163(1), 28–40 (2006).
  MedlineGoogle Scholar
• 26 McMahon FJ, Buervenich S, Charney D et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment, Am. J. Hum. Genet. 78(5), 804–814 (2006).
  Medline CASGoogle Scholar
• 27 Adkins DE, Aberg K, McClay JL et al. A genomewide association study of citalopram response in major depressive disorder – a psychometric approach. Biol. Psychiatry 68(6), e25–e27 (2010).
  MedlineGoogle Scholar
• 28 Lee JS, Kim JH, Bae JS et al. Association analysis of UBE3C polymorphisms in Korean aspirin-intolerant asthmatic patients. Ann. Allergy Asthma Immunol. 105(4), 307–312 (2010).
  Medline CASGoogle Scholar
• 29 Ordway GA, Szebeni A, Chandley MJ et al. Low gene expression of bone morphogenetic protein 7 in brainstem astrocytes in major depression, Int. J. Neuropsychopharmacol. 15(7), 855–868 (2012).
  Medline CASGoogle Scholar
• 30 Esaki K, Kondo K, Hatano M et al. Further evidence of an association between a genetic variant in BMP7 and treatment response to SSRIs in major depressive disorder. J. Hum. Genet. 58(8), 568–569 (2013).
  Medline CASGoogle Scholar
• 31 Logue MW, Baldwin C, Guffanti G et al. A genome-wide association study of post-traumatic stress disorder identifies the retinoid-related orphan receptor alpha (RORA) gene as a significant risk locus. Mol. Psychiatry 18(8), 937–942 (2013).
  Medline CASGoogle Scholar
• 32 Lavebratt C, Sjöholm LK, Partonen T, Schalling M, Forsell Y. PER2 variantion is associated with depression vulnerability. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B(2), 570–581 (2010).
  Medline CASGoogle Scholar
• 33 Terracciano A, Tanaka T, Sutin AR et al. Genome-wide association scan of trait depression. Biol. Psychiatry 68(9), 811–817 (2010).
  Medline CASGoogle Scholar
• 34 Murphy E, Hou L, Maher BS et al. Race, genetic ancestry and response to antidepressant treatment for major depression. Neuropsychopharmacology 38(13), 2598–2606 (2013).
  Medline CASGoogle Scholar
• 35 Bovolenta P, Fernaud-Espinosa I. Nervous system proteoglycans as modulators of neurite outgrowth. Prog. Neurobiol. 61(2), 113–132 (2000).
  Medline CASGoogle Scholar
• 36 Sulkava S, Ollila HM, Ahola K et al. Genome-wide scan of job-related exhaustion with three replication studies implicate a susceptibility variant at the UST gene locus. Hum. Mol. Genet. 22(16), 3363–3372 (2013).
  Medline CASGoogle Scholar
• 37 Rudge JS, Eaton MJ, Mather P, Lindsay RM, Whittemore SR. CNTF induces raphe neuronal precursors to switch from a serotonergic to a cholinergic phenotype in vitro. Mol. Cell Neurosci. 7(3), 204–221 (1996).
  Medline CASGoogle Scholar
• 38 Powell TR, Schalkwyk LC, Heffernan AL et al. Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response. Eur. Neuropsychopharmacol. 23(9), 1105–1114 (2013).
  Medline CASGoogle Scholar
• 39 Powell TR, Smith RG, Hackinger S et al. NA methylation in interleukin-11 predicts clinical response to antidepressants in GENDEP. Transl. Psychiatry 3, e300 (2013).
  Medline CASGoogle Scholar
• 40 GENDEP Investigators, MARS Investigators, STAR*D Investigators et al. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am. J. Psychiatry 170(2), 207–217 (2013).
  MedlineGoogle Scholar
• 41 Watkins PA, Maiguel D, Jia Z, Pevsner J. Evidence for 26 distinct acyl-coenzyme A synthetase genes in the human genome. J. Lipid Res. 48(12), 2736–2750 (2007).
  Medline CASGoogle Scholar
• 42 Rohde HM, Cheong FY, Konrad G, Paiha K, Mayinger P, Boehmelt G. The human phosphatidylinositol phosphatase SAC1 interacts with the coatomer I complex. J. Biol. Chem. 278(52), 52689–52699 (2003).
  Medline CASGoogle Scholar
• 43 Sato K, Yomogida K, Wada T et al. Type XXVI collagen, a new member of the collagen family, is specifically expressed in the testis and ovary. J. Biol. Chem. 277(40), 37678–37684 (2002).
  Medline CASGoogle Scholar
• 44 Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 292(3), 338–343 (2004).
  Medline CASGoogle Scholar
• 45 Licinio J, Wong ML. Depression, antidepressants, and suicidality: a critical appraisal. Nat. Rev. Drug Discov. 4(2), 165–171 (2005).
  Medline CASGoogle Scholar
• 46 Fessler JH, Kramerova I, Kramerov A, Chen Y, Fessler LI. Papilin, a novel component of basement membranes, in relation to ADAMTS metalloproteases and ECM development. Int. J. Biochem. Cell Biol. 36(6), 1079–1084 (2004).
  Medline CASGoogle Scholar
• 47 Martins-de-Souza D, Maccarrone G, Wobrock T et al. Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J. Psychiatr. Res. 44(16), 1176–1189 (2010).
  MedlineGoogle Scholar
• 48 Ward LD, Kellis M. Interpreting noncoding genetic variation in complex traits and human disease. Nat. Biotechnol. 30(11), 1095–1106 (2012).
  Medline CASGoogle Scholar
• 49 Nebert DW, Zhang G, Vesell ES. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab. Rev. 40(2), 187–224 (2008).
  Medline CASGoogle Scholar
• 50 Spencer CC, Su Z, Donnelly P, Marchini J. Designing genome-wide association studies: sample size, power, imputation, and the choice of genotyping chip. PLoS Genet. 5(5), e1000477 (2009).
  MedlineGoogle Scholar
• 51 Perlis RH, Moorjani P, Fagerness J et al. Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study. Neuropsychopharmacology 33(12), 2810–2819 (2008).
  Medline CASGoogle Scholar
• 52 Manolio TA, Collins FS, Cox NJ et al. Finding the missing heritability of complex diseases. Nature 461(7265), 747–753 (2009).
  Medline CASGoogle Scholar
• 53 Cirulli ET, Goldstein DB. Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat. Rev. Genet. 11(6), 415–425 (2010).
  Medline CASGoogle Scholar
• 54 Wheeler DA, Srinivasan M, Egholm M et al. The complete genome of an individual by massively parallel DNA sequencing. Nature 452(7189), 872–876 (2008).
  Medline CASGoogle Scholar
• 55 Bamshad MJ, Ng SB, Bigham AW et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat. Rev. Genet. 12(11), 745–755 (2011).
  Medline CASGoogle Scholar
• 56 Lin E, Hwang Y, Chen EY. Gene–gene and gene–environment interactions in interferon therapy for chronic hepatitis C. Pharmacogenomics 8(10), 1327–1335 (2007).
  CASGoogle Scholar
• 57 Bell JT, Wallace C, Dobson R et al. Two-dimensional genome-scan identifies novel epistatic loci for essential hypertension. Hum. Mol. Genet. 15(8), 1365–1374 (2006).
  Medline CASGoogle Scholar
• 58 Carlborg O, Haley CS. Epistasis: too often neglected in complex trait studies Nature 5(8), 618–625 (2004).
  CASGoogle Scholar
• 59 Lin E, Hwang Y, Liang KH, Chen EY. Pattern-recognition techniques with haplotype analysis in pharmacogenomics. Pharmacogenomics 8(1), 75–83 (2007).
  CASGoogle Scholar
• 60 Lin E, Tsai SJ. Gene–gene interactions in a context of individual variability in antipsychotic drug pharmacogenomics. Curr. Pharmacogenomics Person. Med. 9(4), 323–331 (2011).
  CASGoogle Scholar
• 61 Lin E, Tsai SJ. Novel diagnostics R&D for public health and personalized medicine in Taiwan: current state, challenges and opportunities. Curr. Pharmacogenomics Person. Med. 10(3), 239–246 (2012).
  CASGoogle Scholar
• 62 Lin E. Novel drug therapies and diagnostics for personalized medicine and nanomedicine in genome science, nanoscience, and molecular engineering. Pharmaceutical Regulatory Affairs: Open Access 1, e116 (2012).
  Google Scholar
• 63 Autry AE, Adachi M, Nosyreva E et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475(7354), 91–95 (2011).
  Medline CASGoogle Scholar
• 64 Krystal JH, Sanacora G, Duman RS. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol. Psychiatry 73(12), 1133–1141 (2013).
  Medline CASGoogle Scholar
• 65 Flight MH. Mood disorders: targeting protein synthesis for fast antidepressant action. Nat. Rev. Drug Discov. 10(8), 577 (2011).
  Medline CASGoogle Scholar
• 66 Huang CC, Wei IH, Huang CL et al. Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. Biol. Psychiatry 74(10), 734–741 (2013).
  Medline CASGoogle Scholar
• 67 Swen JJ, Huizinga TW, Gelderblom H et al. Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med. 4(8), e209 (2007).
  MedlineGoogle Scholar
• 68 Bartlett G, Zgheib N, Manamperi A et al. Pharmacogenomics in primary care: a crucial entry point for global personalized medicine? Curr. Pharmacogenomics Person. Med. 10(2), 101–105 (2012).
  Medline CASGoogle Scholar
• 69 Smits KM, Smits LJ, Schouten JS, Peeters FP, Prins MH. Does pretreatment testing for serotonin transporter polymorphisms lead to earlier effects of drug treatment in patients with major depression? A decision-analytic model. Clin. Ther. 29(4), 691–702 (2007).
  Medline CASGoogle Scholar
• 70 Couzin J. Science and commerce. Gene tests for psychiatric risk polarize researchers. Science 319(5861), 274–277 (2008).
  Medline CASGoogle Scholar
• 71 Pate HN, Ursan ID, Zueger PM, Cavallari LH, Pickard AS. Stakeholder views on pharmacogenomic testing. Pharmacotherapy 34(2), 151–165 (2014).
  MedlineGoogle Scholar
• 72 Serretti A, Kato M, Kennedy JL. Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics J. 8(2), 90–100 (2008).
  Medline CASGoogle Scholar
• 73 Shifman S, Bhomra A, Smiley S et al. A whole genome association study of neuroticism using DNA pooling. Mol. Psychiatry 13(3), 302–312 (2008).
  Medline CASGoogle Scholar
• 74 Heck A, Lieb R, Unschuld PG et al. Evidence for associations between PDE4D polymorphisms and a subtype of neuroticism. Mol. Psychiatry 13(9), 831–832 (2008).
  Medline CASGoogle Scholar
• 75 Fass DM, Schroeder FA, Perlis RH, Haggarty SJ. Epigenetic mechanisms in mood disorders: targeting neuroplasticity. Neuroscience 264, 112–130 (2014).
  Medline CASGoogle Scholar
• 76 Menke A, Binder EB. Epigenetic alterations in depression and antidepressant treatment. Dialogues Clin. Neurosci. 16(3), 395–404 (2014).
  MedlineGoogle Scholar
• 77 Lin E, Hwang Y, Wang SC, Gu ZJ, Chen EY. An artificial neural network approach to the drug efficacy of interferon treatments. Pharmacogenomics 7(7), 1017–1024 (2006).
  CASGoogle Scholar
• 78 Serretti A, Smerald E. Neural network analysis in pharmacogenetics of mood disorders. BMC Med. Genet. 5, 27 (2004).
  MedlineGoogle Scholar
• 79 Lin E, Hsu SY. A Bayesian approach to gene-gene and gene-environment interactions in chronic fatigue syndrome. Pharmacogenomics 10(1), 35–42 (2009).
  CASGoogle Scholar